The FDA on Friday signed off on Johnson & Johnson’s single-tablet combination therapy of macitentan and tadalafil for the treatment of pulmonary arterial hypertension (PAH) in adults. The drug will be sold under the brand name Opsynvi.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,